Healthy Extracts Valuation

Q: What is the Fair Price of HYEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

HYEX ($2.16) is trading below our estimate of [[fair value]] ($7.04)

Is HYEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HYEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HYEX ($2.16) is trading below our estimate of fair value ($7.04)

Significantly Below Fair Value: HYEX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HYEX?

Key metric: As HYEX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HYEX. This is calculated by dividing HYEX's market cap by their current revenue.
What is HYEX's PS Ratio?
PS Ratio	2.1x
Sales	US$3.01m
Market Cap	US$3.62m

HYEX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.5x
Enterprise Value/EBITDA	-14.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does HYEX's PS Ratio compare to its peers?

The above table shows the PS ratio for HYEX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.3x
STEK Stemtech	0.5x	n/a	US$2.9m
SISI Shineco	0.3x	n/a	US$3.3m
LIFD LFTD Partners	0.2x	n/a	US$8.5m
UPXI Upexi	0.05x	-13.5%	US$4.1m
HYEX Healthy Extracts	2.1x	n/a	US$3.6m

Price-To-Sales vs Peers: HYEX is expensive based on its Price-To-Sales Ratio (2.1x) compared to the peer average (0.3x).

Price to Sales Ratio vs Industry

How does HYEX's PS Ratio compare vs other companies in the US Personal Products Industry?

28 Companies	Price / Sales	Estimated Growth	Market Cap
HLF Herbalife	0.2x	1.8%	US$778.11m
NUS Nu Skin Enterprises	0.2x	-0.06%	US$377.31m
SKIN Beauty Health	0.6x	5.7%	US$200.46m
MED Medifast	0.3x	-13.4%	US$184.49m

28 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: HYEX is expensive based on its Price-To-Sales Ratio (2.1x) compared to the US Personal Products industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is HYEX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HYEX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate HYEX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Ascend Wellness Holdings

US$100.8m

Engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States.

AAWH

US$0.47

-17.0%

-59.9%

Kimberly-Clark de México S. A. B. de C. V

Mex$86.8b

Manufactures, distributes, and sells disposable products in Mexico.

KCDM.F

Mex$1.45

n/a

Beauty Health

US$200.5m

Designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide.

SKIN

US$1.62

-12.7%

-27.4%